staceywhite, Author at European Medical Journal - Page 29 of 195

20 Dec 2024

Which Therapies Result in the Greatest Reductions in HbA1c and Body Weight?

A network meta-analysis of incretin-based therapies in patients with type 2 diabetes

Achieving With Confidence In Patients with ALGS

KAYFANDA is now indicated for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS) aged 6 months or older…

Reducing the CV Risks of Smoking

Smoking is a major risk factor for cardiovascular disease (CVD) and responsible for around 25% of all CVD-related deaths worldwide…

Neoadjuvant I-O for Resectable NSCLC

Which ICS/LABA for Moderate Asthma?

A promotional GSK-sponsored symposium invited three experts to discuss their main considerations when selecting an inhaled corticosteroid…

A Guide to Chronic Hand Eczema

Chronic Hand Eczema (CHE) is a condition that can go under-recognized despite its significant impact on patients. With l.imited guidance..

Understanding Generalised Pustular Psoriasis: Chronicity, Diversity, Heterogeneity, and Beyond Physical Symptoms

This video from Boehringer Ingelheim focuses on the chronic nature of generalised pustular psoriasis (GPP). It features insights from…

The CORE-VNS study: Design and Interim Analysis

This article summarises a LivaNova-sponsored symposium entitled ‘The Power of Real-World Evidence with CORE-VNS’, delivered on 7th…

Targeting IgAN with Sparsentan + a SGLT2i

IgA nephropathy (IgAN) can impact life expectancy in those affected, thus efficacious treatment is key. Endothelin 1 (ET-1) and angiotensin…

IL-5 in Type 2 Inflammatory Diseases

Type 2 inflammation is involved in severe asthma (SA), chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic granulomatosis…